Loading…
PMCB
PharmaCyte Biotech, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 71715X203
$0.52-4.66%Price as of Aug 29, 18:42 UTC · updated once a day, after the close
Key metrics
- Market cap
- $5.53M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.2x
- Dividend yield
- —
- Payout
- —
- EPS
- -$2.64
- ROE
- -44.72%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.68
- 52-week high
- $1.51
- 52-week low
- $0.50
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -84.4% over 5Y.
today you would have $139.12▼ -86.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 14 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $0.44 | $0.72 | $1.57 | $2.16 | $2.93 | $2.50 | $10.39 | $62.78 | $57.35 | $86.49 | $230.79 | $71.30 | $279.00 | $158.10 | |
| P/E | — | — | 0.2x | — | — |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| NCNANuCana plc | $1.33 | 0.0x | 0.2x | — | -70.26% | $5.54M |
| PULMPulmatrix, Inc. | $1.51 | — | 3.5x | — | -98.35% | $5.51M |
| JUNSJupiter Neurosciences Inc | $4.18 | — | — | — | -1888.70% | $5.51M |
| CVKDCadrenal Therapeutics, Inc. | $1.54 |
About the company
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
- 2
- Las Vegas, United States
Company description provided by Yahoo Finance.